Navigation Links
New drug to tackle fat problems

Medical researchers at the University of Sheffield have defined the structure of a key part of the human obesity receptor- an essential factor in the regulation of body fat- which could help provide new treatments for the complications of obesity and anorexia.

This major advance in research, published in the journal Structure, will greatly enhance the ability to generate drugs which can both block and stimulate the receptor for the obesity hormone leptin. This could have life-changing effects on people suffering from the complications of obesity and malnutrition.

Researchers have solved the challenging crystal structure of the leptin-binding domain of the obesity receptor using state of the art X-ray crystallography, helping them to work out how to block or stimulate the receptor. Leptin, the obesity hormone, is produced by fat and excess leptin predisposes overweight people to conditions such as multiple sclerosis, cancer and heart disease whilst a deficiency in leptin, as occurs in malnutrition, results in infertility and immunodeficiency.

Blocking the receptor, and therefore the excessive actions of leptin, could prevent the complications of obesity and stimulating the receptor may improve fertility and the immune response.

Professor Richard Ross, Professor of Endocrinology at the University of Sheffield said: "This pioneering research gives us the potential to generate new drugs that could treat conditions and diseases associated with obesity such as Multiple Sclerosis, diabetes and cardiovascular disease.

"Modulating the actions of the obesity receptor provides a novel approach to the treatment of conditions associated with both obesity and anorexia and has the potential to make a massive difference to millions of people whose quality of life and health is hindered by obesity or malnutrition."

Controlling appetite is a fundamental basic physiological drive which in turn is connected to many other aspects of physiology, in particular fertility and the immune response.

Professor Pete Artymiuk, from the University of Sheffield's Department of Molecular Biology and Biotechnology, said: "The human obesity receptor binds the hormone leptin and together they play a key role in regulating appetite, fertility, and immunity.

"Using X-ray crystallography we have solved the structure of the leptin-binding domain of the receptor bound to a potential therapeutic antibody that blocks leptin binding. This is the first crystal structure for any part of this important receptor.

"Because we now know the precise atomic structure of the receptor we can begin to design drug molecules that can alter its activity. This can be useful in the treatment of a variety of diseases ranging from obesity to autoimmune diseases including multiple sclerosis."

Contact: Amy Pullan
University of Sheffield

Related medicine news :

1. New developments in nanotechnology tackle the 2 biggest problems associated with chemotherapy
2. Founder and President of BOMF, Anne Mahlum, Speaks on How Running Helps to Tackle Homelessness, at National Press Club
3. Get up, get out and go: NC State research tackles childhood obesity
4. Kay's Naturals Answers Obama's Call to Tackle Childhood Obesity
5. Medical schools partner to tackle barriers to minority participation in cancer clinical trials
6. Iowan Tackles Everest and More in Unprecedented Adventure
7. Breast Cancer Survivor Tackles the Missing Link: Inspiring Event Offers Women Real Life Advice to Thrive After Medical Treatment Ends
8. Recent Book Moves Beyond Defensive Medicine, Tackles Entitlement Reform
9. Anemia tougher to tackle in black children with kidney disease
10. Global Alliance of Technological Universities (GlobalTech) to tackle Grand Challenges
11. Experts call for urgent action to tackle strong links between impotence and heart disease
Post Your Comments:
(Date:10/13/2015)... Angeles, CA (PRWEB) , ... October 13, 2015 , ... ... Managed Care, a recent study has shown that women who successfully lose weight with ... women in the United States each year. The article notes that anywhere from 40 ...
(Date:10/13/2015)... ... October 13, 2015 , ... Symposium Chairman, Dr. Rod J. Rohrich is pleased ... to be held March 2nd and 3rd, 2016. The annual meeting, along with the ... cosmetic physicians from around the world. , Key topics at this year's event will ...
(Date:10/13/2015)... ... 13, 2015 , ... Relay (, a technology company that ... significant contract that will provide its award-winning private messaging solution to Independence Blue ... success of its Relay program, IBX Wire™, which now has over 550,000 members ...
(Date:10/13/2015)... ... October 13, 2015 , ... NavaFit Inc. today announced the ... others to train with, participate in local fitness & sporting events, and stay ... , “As high medical costs drive us to get more serious about fitness and ...
(Date:10/13/2015)... ... , ... Protein is essential to good health. You need it to make ... much protein does the average man need in order to stay healthy? , ... issue of Harvard Men's Health Watch . Most Americans get about 15% of ...
Breaking Medicine News(10 mins):
(Date:10/13/2015)... Health Gorilla ( ) today announced the ... a secure platform for clinical data and communications poised to ... manage healthcare in the US. The launch follows the closing ... total of $4.4M raised to date, with Data Collective ... , Harris Barton , Orfin Ventures and ...
(Date:10/13/2015)... --> --> Opportunities for ... Asthma and COPD Therapies market? Which areas are going to ... report shows you potential revenues to 2025, assessing data, trends, ... tables, charts, and graphs. Discover the most lucrative areas in ... lets you assess forecasted sales at overall world market and ...
(Date:10/13/2015)... SPRINGS, N.C. , Oct. 13, 2015  Yesterday ... NVS Influenza Vaccines Holly Springs manufacturing site located in ... Since 2014, the facility has produced Flucelvax ® ... has the potential for faster start-up and is not ... 2015 CSL Limited acquired the influenza vaccines business of ...
Breaking Medicine Technology: